CTOs on the Move

AdviNOW Medical

www.advinow.com

 
Our AI & AR powered technology reduces medical practice overhead, accelerates patient throughput, improves efficiency, and speeds up data collection.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.advinow.com
  • 10446, N 74th St
    Scottsdale, AZ USA 85258
  • Phone: 602.351.5869

Executives

Name Title Contact Details

Similar Companies

Meridian Behavioral Healthcare,

Serving North Central Florida, covering a geographic area of almost 7,500 square miles that is largely rural and sparsely populated, serving the following 12 counties: Alachua, Baker, Bradford, Columbia, Dixie, Gilchrist, Hamilton, Lafayette, Levy, Put...

Integrum

Integrum has since its foundation been helping amputees towards an improved quality of life. We specialize in the osseointegration method.

Rain International

Rain International is a company that produces and sells seed-powered products that promote health and wellness through all-natural ingredients.

Alliance Protein Laboratories

Alliance Protein Laboratories is a Thousand Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Edesa Biotech Incorporated

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.